Skip to main contentSkip to navigationSkip to search

Press releases and news

2023

Camurus’ Interim Report Second Quarter 2023

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial

Camurus accepted as participant of the United Nations Global Compact

Change in number of shares and votes in Camurus

Camurus to present at Jefferies 2023 Healthcare Conference New York

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Resolutions at the annual general meeting 2023 in Camurus

Camurus’ Interim Report January-March 2023

Camurus appoints Alberto Pedroncelli as Chief Medical Officer

Notice of annual general meeting 2023 in Camurus AB (publ)

Camurus Annual Report for 2022

Camurus’ Full Year Report 2022

Camurus withdraws variation application for CAM2038 to include chronic pain

2022

Change in number of shares and votes in Camurus

Camurus announces PDUFA date for Brixadi™ NDA for the treatment of opioid use disorder in the US

Camurus announces that Braeburn resubmits NDA for Brixadi™ in the US

Camurus to present at Jefferies 2022 Healthcare Conference London

Camurus’ Interim Report Third Quarter 2022

Camurus supports two Global Awareness Days for rare diseases

Load more press releases

Subscribe

Get the latest news from Camurus

Subscribe to receive latest news from Camurus directly to your email. 

Information types

By subscribing to news from Camurus, you agree to our privacy policy.

Thank you. You will get an e-mail message to activate your subscription.